Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group AG    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
02/22/2021 02/23/2021 02/24/2021 02/25/2021 02/26/2021 Date
591.2(c) 585.2(c) 592.4(c) 583.8(c) 573.8 Last
178 611 310 483 215 616 169 127 249 448 Volume
-1.60% -1.01% +1.23% -1.45% -1.71% Change
More quotes
Financials
Sales 2020 6 161 M 6 800 M 6 800 M
Net income 2020 844 M 932 M 932 M
Net Debt 2020 2 851 M 3 146 M 3 146 M
P/E ratio 2020 50,5x
Yield 2020 0,50%
Sales 2021 4 983 M 5 500 M 5 500 M
Net income 2021 1 073 M 1 184 M 1 184 M
Net Debt 2021 1 790 M 1 976 M 1 976 M
P/E ratio 2021 41,0x
Yield 2021 0,54%
Capitalization 43 370 M 47 991 M 47 868 M
EV / Sales 2020 7,50x
EV / Sales 2021 9,06x
Nbr of Employees 14 000
Free-Float 99,6%
More Financials
Company
Lonza Group is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals and nutritional ingredients (70.4%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, nutritional ingredients, etc. In addition, the group offers dosage solutions for... 
More about the company
Notations Surperformance© of Lonza Group AG
Trading Rating : Investor Rating :
More Ratings
All news about LONZA GROUP AG
02/24LONZA : is recognised by Ethisphere as One of the World's Most Ethical Companies..
AQ
02/23LONZA : is recognised by Ethisphere ® as One of the World's Most Ethical Compani..
PU
02/16LONZA : Expands Solid Form Selection Services at US Site
MT
02/16PolyPeptide names new CEO before likely Swiss IPO during 2021
RE
02/16LONZA : Expands Solid Form Services for Small Molecule Drugs
PU
02/16LONZA : Deutsche Bank Lifts Price Target on Lonza Group, Maintains Buy Recommend..
MT
02/09GLOBAL MARKETS LIVE: Still reeling from Tesla’s announcement
02/09LONZA : Mirabaud Securities Lifts Price Target on Lonza Group, Maintains Buy Rec..
MT
02/09LONZA : Inks $4.7 Billion Sale of Specialty Ingredients Unit to Private Equity D..
MT
02/09Bain Capital, Cinven Buy Lonza's Specialty Ingredients Division
DJ
02/09MARKET CHATTER : Eurazeo Plans Sale of $2.42 Billion Pharma Ingredients Business
MT
02/08LONZA : Selling Specialty Ingredients Unit to Bain Capital, Cinven for $4.7 Bill..
MT
02/08LONZA : Signs Agreement to Divest Specialty Ingredients Business to Bain Capital..
PU
02/08REFILE-French pharma ingredients maker Seqens prepped for sale - sources
RE
02/04South Korea in talks with Moderna over $200 million investment to build vacci..
RE
More news
News in other languages on LONZA GROUP AG
02/23Aktien Schweiz mit Abschlägen - Credit Suisse fester
02/23Ça tourne, action !
02/23AVIS D'ANALYSTES DU JOUR : Adidas, Danone, Renault, Siemens, Lonza, Crédit Suiss..
02/22Aktien Schweiz zu Wochenbeginn knapp behauptet
02/17L'UE conclut un deuxième contrat avec Moderna pour 300 millions de doses
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Stock Trading Strategies
LONZA GROUP AG - 2020
The stock is approaching a major resistance level
BUY
More Stock Trading Analysis
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 652,38 CHF
Last Close Price 583,80 CHF
Spread / Highest target 33,1%
Spread / Average Target 11,7%
Spread / Lowest Target -11,3%
EPS Revisions
Managers and Directors
NameTitle
Pierre-Alain Ruffieux Chief Executive Officer
Rodolfo Savitzky Chief Financial Officer
Albert M. Baehny Chairman
Werner J. Bauer Independent Director
Barbara May Richmond No-Executive Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP AG2.64%47 991
MODERNA, INC.38.59%57 295
IQVIA HOLDINGS INC.7.47%37 221
CELLTRION, INC.-14.21%34 686
SEAGEN INC.-14.30%28 084
HANGZHOU TIGERMED CONSULTING CO.,LTD-7.61%20 223